Acro Biomedical (ACBM) Liabilities and Shareholders Equity (2015 - 2025)

Acro Biomedical's Liabilities and Shareholders Equity history runs 11 years deep, the most recent figure standing at $14098.0 for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity fell 55.91% year-over-year to $14098.0; the TTM figure through Dec 2025 stood at $96873.0 (down 41.9% YoY), while the FY2025 annual figure was $14098.0, down 55.91% from the prior year.
• Liabilities and Shareholders Equity was $14098.0 for Q4 2025 at Acro Biomedical, up from $4323.0 in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $938874.0 in Q1 2021 to a low of $4323.0 in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $364818.5 across 5 years, with a median of $298803.5 in 2023.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity sank 97.04% in 2023, then surged 103.27% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $761077.0 in 2021, then slipped by 9.67% to $687486.0 in 2022, then slumped by 91.5% to $58459.0 in 2023, then tumbled by 45.31% to $31974.0 in 2024, then tumbled by 55.91% to $14098.0 in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $14098.0 (Q4 2025), $4323.0 (Q3 2025), and $53277.0 (Q2 2025), per Business Quant data.